Actinium Pharmaceuticals Inc (ATNM)

[dia76ca]

There are many near term milestones.
1.Topline SIERRA data Q3 2022 (July?) already Fast Tracked in US and Europe
2. SIERRA BLA filing 1H 2023
3.Iomab-ACT CAR-T data 2022
4. GeneTx data 2022
5.Actimab-A + CLAG update 1H 2022
6.Actimab-A + Venetudax ph.2 1H 2022
7.AWE platform advances 2022
The very attractive European partnership should be followed by an US and ROW partnership. Or perhaps by a BO. Astellas is the 1000 lb. Gorilla in the room. If they like what they have seen so far they could buy up the whole company for a few $Billion. Chicken feed for them...but a nice return for Actinium investors!
No wonder H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and set a price target of $45.00.